Book contents
- Infectious Diseases, Microbiology and Virology
- Infectious Diseases, Microbiology and Virology
- Copyright page
- Contents
- Preface
- Reference Ranges
- Abbreviations
- Chapter 1 Biology of Bacteria, Viruses, Fungi and Parasites and the Host–Pathogen Interactions
- Chapter 2 Microbiology and Virology Laboratory Practice
- Chapter 3 Health and Safety for Infectious Diseases, Microbiology and Virology
- Chapter 4 Principles of Public Health in Relation to Infectious Diseases, Microbiology and Virology
- Chapter 5 Infection Prevention and Control
- Chapter 6 Important Clinical Syndromes Presenting from the Community and within Healthcare Organisations
- Chapter 7 Understanding the Use of Antimicrobial Agents
- Chapter 8 Vaccination
- Chapter 9 The Management of HIV Infection, Opportunistic Infections and Complications of Other Causes of Immunocompromise
- Chapter 10 Travel and Geographical Health; Imported Infection and the Provision of Pre-travel Health Advice
- Index
- References
Chapter 9 - The Management of HIV Infection, Opportunistic Infections and Complications of Other Causes of Immunocompromise
Published online by Cambridge University Press: 19 December 2019
Book contents
- Infectious Diseases, Microbiology and Virology
- Infectious Diseases, Microbiology and Virology
- Copyright page
- Contents
- Preface
- Reference Ranges
- Abbreviations
- Chapter 1 Biology of Bacteria, Viruses, Fungi and Parasites and the Host–Pathogen Interactions
- Chapter 2 Microbiology and Virology Laboratory Practice
- Chapter 3 Health and Safety for Infectious Diseases, Microbiology and Virology
- Chapter 4 Principles of Public Health in Relation to Infectious Diseases, Microbiology and Virology
- Chapter 5 Infection Prevention and Control
- Chapter 6 Important Clinical Syndromes Presenting from the Community and within Healthcare Organisations
- Chapter 7 Understanding the Use of Antimicrobial Agents
- Chapter 8 Vaccination
- Chapter 9 The Management of HIV Infection, Opportunistic Infections and Complications of Other Causes of Immunocompromise
- Chapter 10 Travel and Geographical Health; Imported Infection and the Provision of Pre-travel Health Advice
- Index
- References
Summary
Patients living with human immunodeficiency virus (HIV) have particular health needs relating to their diagnosis, the opportunistic infections which can affect them, and the chronic disease management of their condition which is impacted by the disease process itself and the medication used to control it. Practitioners working with patients living with human immunodeficiency virus must hold knowledge of the pathophysiology and natural history of the disease, the therapeutic options available for virological control and the likely complication from HIV and the medications. Practitioners must be able to safely monitor and interpret the test results of patients living with human immunodeficiency virus. They must also be able to advise on strategies to decrease onwards transmission of HIV, including pre-and post-exposure prophylaxis. Practitioners managing patients living with human immunodeficiency virus must be able to identify and treat the opportunistic infections which may arise.
- Type
- Chapter
- Information
- Infectious Diseases, Microbiology and VirologyA Q&A Approach for Specialist Medical Trainees, pp. 187 - 209Publisher: Cambridge University PressPrint publication year: 2019
References
Further Reading
INSIGHT START study Group, Lundgren, JD, Babiker, AG, Gordin, F, Emery, S, Grund, B, Sharma, S, Avihingsanon, A, Cooper, DA, Fätkenheuer, G, Llibre, JM, Molina, JM, Munderi, P, Schechter, M, Wood, R, Klingman, KL, Collins, S, Lane, HC, Phillips, AN, Neaton, JD. Initiation of antiretroviral therapy in early asymptomatic HIV infection. N Engl J Med. 2015;373(9):795–807.Google Scholar
Further Reading
Kalayjian, RC. The treatment of HIV-associated nephropathy. Adv Chronic Kidney Dis. 2010;17(1):59–71.Google Scholar
Further Reading
Burton, DR, Mascola, JR. Antibody responses to envelope glycoproteins in HIV-1 infection. Nat Immunol. 2015;16:571–576.Google Scholar
The INSIGHT START Study Group. Initiation of antiretroviral therapy in early asymptomatic HIV infection. N Engl J Med. 2015;373:795–807.Google Scholar
Further Reading
Nelson, M, Dockrell, D, Edwards, S; BHIVA guidelines subcommittee. British HIV Association and British Infection Association guidelines for the treatment of opportunistic infection in HIV-seropositive individuals 2011. HIV Med. 2011;12(S2):1–140.CrossRefGoogle Scholar
Further Reading
Nelson, M, Dockrell, D, Edwards, S; BHIVA Guidelines Subcommittee. British HIV Association and British Infection Association guidelines for the treatment of opportunistic infection in HIV-seropositive individuals 2011. HIV Med. 2011;12(S2):1–140.CrossRefGoogle Scholar
Further Reading
Bower, M, Palfreeman, A, Alfa-Wali, M, Bunker, C, Burns, F, Churchill, D, Collins, S, Cwynarski, K, Edwards, S, Fields, P, Fife, K, Gallop-Evans, E, Kassam, S, Kulasegaram, R, Lacey, C, Marcus, R, Montoto, S, Nelson, M, Newsom-Davis, T, Orkin, C, Shaw, K, Tenant-Flowers, M, Webb, A, Westwell, S, Williams, M. British HIV association guidelines for HIV-associated malignancies 2014. HIV Med. 2014;15(S2):1–92.Google Scholar
Further Reading
Bower, M, Palfreeman, A, Alfa-Wali, M, Bunker, C, Burns, F, Churchill, D, Collins, S, Cwynarski, K, Edwards, S, Fields, P, Fife, K, Gallop-Evans, E, Kassam, S, Kulasegaram, R, Lacey, C, Marcus, R, Montoto, S, Nelson, M, Newsom-Davis, T, Orkin, C, Shaw, K, Tenant-Flowers, M, Webb, A, Westwell, S, Williams, M. British HIV association guidelines for HIV-associated malignancies 2014. HIV Med. 2014;15(S2):1–92.Google Scholar
Further Reading
Nelson, M, Dockrell, D, Edwards, S. British HIV Association and British Infection Association guidelines for the treatment of opportunistic infection in HIV-seropositive individuals 2011. HIV Med. 2011;12(S2):1–140.Google Scholar
Further Reading
Churchill, D, Waters, L, Ahmed, N, Angus, B, Boffito, M, Bower, M, Dunn, D, Edwards, S, Emerson, C, Fidler, S, Fisher, M, Horne, R, Khoo, S, Leen, C, Mackie, N, Marshall, N, Monteiro, F, Nelson, M, Orkin, C, Palfreeman, A, Pett, S, Phillips, A, Post, F, Pozniak, A, Reeves, I, Sabin, C, Trevelion, R, Walsh, J, Wilkins, E, Williams, I, Winston, A. British HIV association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2015. HIV Med. 2016;17(S4):S2–S104.Google Scholar
Further Reading
Churchill, D, Waters, L, Ahmed, N, Angus, B, Boffito, M, Bower, M, Dunn, D, Edwards, S, Emerson, C, Fidler, S, Fisher, M, Horne, R, Khoo, S, Leen, C, Mackie, N, Marshall, N, Monteiro, F, Nelson, M, Orkin, C, Palfreeman, A, Pett, S, Phillips, A, Post, F, Pozniak, A, Reeves, I, Sabin, C, Trevelion, R, Walsh, J, Wilkins, E, Williams, I, Winston, A. British HIV association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2015. HIV Med. 2016;17(S4):S2–S104.Google Scholar
Further Reading
De Ruiter, A, Taylor, GP, Clayden, P, Dhar, J, Gandhi, K, Gilleece, Y, Harding, K, Hay, P, Kennedy, J, Low-Beer, N, Lyall, H, Palfreeman, A, O’Shea, S, Tookey, P, Tosswill, J, Welch, S, Wilkins, E. British HIV Association guidelines for the management of HIV infection in pregnant women 2012 (2014 interim review). HIV Med. 2014;15(S4):1–77.Google Scholar
Ford, N, Mofenson, L, Shubber, Z, Calmy, A, Andrieux-Meyer, I, Vitoria, M, Shaffer, N, Renaud, F. Safety of efavirenz in the first trimester of pregnancy: an updated systematic review and meta-analysis. AIDS. 2014;28(S2):S123–S131.Google Scholar
Further Reading
Churchill, D, Waters, L, Ahmed, N, Angus, B, Boffito, M, Bower, M, Dunn, D, Edwards, S, Emerson, C, Fidler, S, Fisher, M, Horne, R, Khoo, S, Leen, C, Mackie, N, Marshall, N, Monteiro, F, Nelson, M, Orkin, C, Palfreeman, A, Pett, S, Phillips, A, Post, F, Pozniak, A, Reeves, I, Sabin, C, Trevelion, R, Walsh, J, Wilkins, E, Williams, I, Winston, A. British HIV association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2015. HIV Med. 2016;17(S4):S2–S104.Google Scholar
Waters, L, Jackson, A, Else, L, Rockwood, N, Newell, S, Back, D, Nelson, M, Gazzard, B, Boffito, M. Switching safely: pharmacokinetics, efficacy and safety of switching efavirenz to maraviroc twice daily I patients on suppressive antiretroviral therapy. Antivir Ther. 2015;20:157–163.Google Scholar
Further Reading
Gilleece, Y, Chadwick, DR, Breuer, J, Hawkins, D, Smit, E, McCrae, LX, Pillay, D, Smith, N, Anderson, J. British HIV association guidelines for antiretroviral treatment of HIV-2 positive individuals 2010. HIV Med. 2010;11:611–619.Google Scholar
Further Reading
Cresswell, F, Waters, L, Briggs, E, Fox, J, Harbottle, J, Hawkins, D, Murchie, M, Radcliffe, K, Rafferty, P, Rodger, A, Fisher, M. UK guideline for the use of HIV post-exposure prophylaxis following sexual exposure, 2015. Int J STD AIDS. 2016;27(9):713–738.Google Scholar
Further Reading
Lopez Bernaldo de Quiros, JC, Miro, JM, Peña, JM, Podzamczer, D, Alberdi, JC, Martínez, E, Cosin, J, Claramonte, X, Gonzalez, J, Domingo, P, Casado, JL, Ribera, E. A randomized trial of the discontinuation of primary and secondary prophylaxis against Pneumocystis carinii pneumonia after highly active antiretroviral therapy in patients with HIV infection. Grupo de Estudio del SIDA 04/98. N Engl J Med. 2001;344(3):159.Google Scholar
Further Reading
Nelson, M, Dockrell, D, Edwards, S. British HIV Association and British Infection Association guidelines for the treatment of opportunistic infection in HIV-seropositive individuals 2011. HIV Med. 2011;12(S2):1–140.Google Scholar
Further Reading
Lenaerts, L, De Clercq, E, Naesens, L. Clinical features and treatment of adenovirus infections. Rev Med Virol. 2008;18(6):357–374.Google Scholar
Further Reading
Caserta, MT, Hall, CB, Schnabel, K, Lofthus, G, Marino, A, Shelley, L, Yoo, C, Carnahan, J, Anderson, L, Wang, H. Diagnostic assays for active infection with human herpesvirus 6 (HHV-6). J Clin Virol. 2010;48(1):55–57.Google Scholar
Further Reading
Pastor, FJ, Guarro, J. Clinical manifestations, treatment and outcome of Paecilomyces lilacinus infections. Clin Microbiol Infect. 2006 Oct;12(10):948–960.Google Scholar
Further Reading
Nucci, M, Marr, KA, Bvehreschild, MJ, de Souza, CA, Velasco, E, Cappellano, P, Carlesse, F, Queiroz-Telles, F, Sheppard, DC, Kindo, A, Cesaro, S, Hamerschlak, N, Solza, C, Heinz, WJ, Schaller, M, Atalla, A, Arikan-Akdagli, S, Bertz, H, Galvão Castro, C Jr, Herbrecht, R, Hoenigl, M, Härter, G, Hermansen, NE, Josting, A, Pagano, L, Salles, MJ, Mossad, SB, Ogunc, D, Pasqualotto, AC, Araujo, V, Troke, PF, Lortholary, O, Cornely, OA, Anaissie, E. Improvement in the outcome of invasive fusariosis in the last decade. Clin Microbiol Infect. 2014;20(6):580–585.Google Scholar
Further Reading
Aguilar-Guisado, M, Espigado, I, Martin-Pena, A, Gudiol, C, Royo-Cebrecos, C, Falantes, J, Vázquez-López, L, Montero, MI, Rosso-Fernández, C, de la Luz Martino, M, Parody, R, González-Campos, J, Garzón-López, S, Calderón-Cabrera, C, Barba, P, Rodríguez, N, Rovira, M, Montero-Mateos, E, Carratalá, J, Pérez-Simón, JA, Cisneros, JM. Optimisation of empirical antimicrobial therapy in patients with haematological malignancies and febrile neutropenia (How Long study): an open-label, randomised, controlled phase 4 trial. Lancet Haematol. 2017;4(12):e573–e583.Google Scholar
Averbuch, D, Orasch, C, Cordonnier, C, Livermore, DM, Mikulska, M, Viscoli, C, Gyssens, IC, Kern, WV, Klyasova, G, Marchetti, O, Engelhard, D, Akova, M. European guidelines for empirical antibacterial therapy for neutropenic patients in the era of growing resistance: summary of the 2011 4th European Conference on Infections in Leukaemia. Haematologica. 2013;98(12):1826–1835.Google Scholar
National Institute for Health and Care Excellence. Neutropenic sepsis: prevention and management in people with cancer. NICE guideline (CG151). 2012. Available at: www.nice.org.uk/guidance/cg151Google Scholar
Further Reading
Patterson, TF, Thompson, GR 3rd, Denning, DW, Fishman, JA, Hadley, S, Herbrecht, R, Kontoyiannis, DP, Marr, KA, Morrison, VA, Nguyen, MH, Segal, BH, Steinbach, WJ, Stevens, DA, Walsh, TJ, Wingard, JR, Young, JA, Bennett, JE. Practice guidelines for the diagnosis and management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America. Clin Infect Dis. 2016;63(4):e1–e60.Google Scholar
Further Reading
Stringer, J, Beard, C, Miller, R, Wakefield, A. A new name (Pneumocystis jirovecii) for pneumocystis from humans. Emerg Infect Dis. 2002;8(9):891–896.CrossRefGoogle Scholar
Further Reading
Mauch, L, Lun, A, O’Gorman, MR, Harris, JS, Schulze, I, Zychlinsky, A, Fuchs, T, Oelschlägel, U, Brenner, S, Kutter, D, Rösen-Wolff, A, Roesler, J. Chronic granulomatous disease (CGD) and complete myeloperoxidase deficiency both yield strongly reduced dihydrorhodamine 123 test signals but can be easily discerned in routine testing for CGD. Clin Chem. 2007;53(5):890.CrossRefGoogle ScholarPubMed
Further Reading
Health Protection Agency. Guidelines for Assessing the Microbiological Safety of Ready-to-Eat Foods. London: Health Protection Agency. 2009. Available at: www.gov.uk/government/publications/ready-to-eat-foods-microbiological-safety-assessment-guidelinesGoogle Scholar
Further Reading
Anders, BJ, Lauer, BA, Paisley, JW, Reller, LB. Double-blind placebo controlled trial of erythromycin for treatment of Campylobacter enteritis. Lancet. 1982;1(8264):131–132.Google Scholar
Janssen, R, Krogfelt, KA, Cawthraw, S, van Pelt, W, Wagenaar, JA, Owen, RJ. Host-pathogen interactions in Campylobacter infections: the host perspective. Clin Microbiol Rev. 2008;21(3):505–518.CrossRefGoogle ScholarPubMed
Further Reading
Heinz, WJ, Buchheidt, D, Chistopeit, M, von Lilienfeld-Toal, M, Cornely, OA, Einsele, H, Karthaus, M, Link, H, Mahlberg, R, Neumann, S, Ostermann, H, Penack, O, Ruhnke, M, Sandherr, M, Schiel, X, Vehreschild, JJ, Weissinger, F, Maschmeyer, G. Diagnosis and empirical treatment of fever of unknown origin (FUO) in adult neutropenic patients: guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Haematology and Medical Oncology (DGHO). Ann Hematol. 2017;96(11):1775–1792.Google Scholar
National Institute for Health and Care Excellence. Neutropenic sepsis: prevention and management in people with cancer. NICE guideline (CG151). 2012. Available at: www.nice.org.uk/guidance/cg151Google Scholar